License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the ...

Madrigal Pharmaceuticals said on Wednesday it has entered into an up to $2 billion global license agreement with CSPC Pharmaceutical to develop an oral GLP-1 drug for a type of liver disease.

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

GLP-1 drugs are widely seen as a transformative treatment, and their vast market potential is now the industry consensus, WuXi AppTec said. The company’s outsourcing model allows it to contribute to ...

Weight gain, low energy and stalled progress at the gym are issues many men face as they get older. But a new wave of ...

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...

Congress on Cardiovascular Disease Prevention features multiple sessions on different methods of treating and preventing ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.